End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.069 AUD | -4.17% | -9.21% | +16.95% |
02-28 | Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Dimerix Appoints Nonexecutive Chair | MT |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 52% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.95% | 42.75M | - | ||
-1.53% | 104B | B+ | ||
+6.68% | 97.47B | B+ | ||
+5.71% | 22.25B | B | ||
-12.82% | 21.68B | B+ | ||
-9.70% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-9.74% | 16.36B | B | ||
+7.50% | 14.39B | C+ | ||
+36.20% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PER Stock
- Ratings Percheron Therapeutics Limited